Process for detergent-free production of outer membrane vesicles of a gram-negative bacterium

Inventors

Van De Waterbeemd, Bas • Van Der Pol, Leonardus Aldolfus

Assignees

Intravacc BV

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-9707286-B2

Patent

Publication Date

2017-07-18

Expiration Date


Abstract

The present invention relates to the fields of medical microbiology and vaccines. In particular the invention relates to a process for detergent-free preparation of outer membrane vesicles (OMV) of Gram negative bacteria for use in vaccines, to OMV obtainable by said process, and to a pharmaceutical composition comprising such OMV. The present invention further relates to the use of OMV of the present invention as a medicament in particular for use in a method for eliciting an immune response.

Core Innovation

The invention relates to a process for producing a detergent-free preparation of bacterial outer membrane vesicles (OMV) for use in vaccines. A population of bacteria of a species of Neisseria is cultivated in culture to stationary growth phase, and OMVs are extracted without detergent-based purification. The OMVs are then recovered by separation of the extracted bacterial OMV from the bacteria.

The process begins incubation at a time at least about 1 hour after onset of the stationary growth phase, using a medium adjusted to or having a pH higher than pH 8.0 and a concentration of a metal chelating agent of between about 1 mM and 100 mM to extract OMV. The detergent-free extraction approach is positioned against detergent-based purification, where detergent can reduce cross-protection and alter vesicle structure, while detergent-free native/supernatant OMV processes can present high LPS toxicity or low yield.

The invention further provides vaccine-related functionality for the recovered detergent-free OMVs, including eliciting immune response and bactericidal responses. Genetically modified Neisseria are described in which lipopolysaccharide (LPS) toxicity is reduced while retaining part of LPS adjuvant activity, and the platform supports use in OMV vaccines including trivalent and nonavalent OMV vaccines.

Claims Coverage

The provided material shows one independent claim, defining the core detergent-free OMV production process, with dependent claims refining extraction parameters and adding optional processing and engineered bacterial properties. Overall, the claim set contains inventive features centered on stationary-phase Neisseria cultivation, detergent-free chelator-based OMV extraction at pH above 8.0 after at least about 1 hour, and OMV recovery by separating OMV from bacteria.

Detergent-free OMV production for vaccine use from stationary-phase Neisseria

A process comprising cultivating a population of Neisseria bacteria in culture to stationary growth phase, then recovering a detergent-free preparation of bacterial outer membrane vesicles (OMV) for use in vaccines by separation of the extracted bacterial OMV from the bacteria.

Chelator-based OMV extraction at pH higher than 8.0 after stationary onset

Beginning at a time at least about 1 hour after onset of the stationary growth phase, incubating the bacteria in a medium adjusted to or having a pH higher than pH 8.0 and a concentration of a metal chelating agent between about 1 mM and 100 mM to extract OMV.

Using EDTA as the metal chelating agent

The process wherein the metal chelating agent is EDTA.

Sterilizing the bacterial OMV

The process further defined to include a step of sterilizing the recovered bacterial OMV.

The claim coverage is anchored by a detergent-free process that extracts Neisseria OMVs using a metal chelating agent in a medium with pH higher than pH 8.0 starting at least about 1 hour after stationary growth phase onset, followed by recovery by separating OMVs from bacteria. Dependent material in the partial content further specifies EDTA as the chelator and adds an optional sterilization step.

Stated Advantages

Detergent-free purification can avoid reduced cross-protection and altered vesicle structure associated with detergent-based purification.

The detergent-free extraction approach is positioned to address limitations of detergent-free native/supernatant OMV processes such as high LPS toxicity or low yield.

Genetically modified Neisseria are described to reduce LPS toxicity while retaining part of LPS adjuvant activity.

The platform is described as supporting immune response elicitation and bactericidal responses, with a possible reduced need for additional adjuvant.

Documented Applications

Use of the detergent-free preparation of bacterial OMVs for vaccines, including immune response elicitation and bactericidal responses.

OMV vaccine formulations described in the document include trivalent and nonavalent OMV vaccines.

Production example described for scalable production to improve yield and purity in the context of the OMV vaccine platform.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.